Johnson & Johnson (JNJ)
| Market Cap | 609.12B +62.4% |
| Revenue (ttm) | 97.93B +8.1% |
| Net Income | 21.04B -7.2% |
| EPS | 8.63 -7.7% |
| Shares Out | 2.41B |
| PE Ratio | 29.33 |
| Forward PE | 20.87 |
| Dividend | $5.36 (2.12%) |
| Ex-Dividend Date | Aug 25, 2026 |
| Volume | 10,167,184 |
| Open | 252.59 |
| Previous Close | 249.97 |
| Day's Range | 251.95 - 255.66 |
| 52-Week Range | 162.30 - 269.43 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 269.95 (+6.68%) |
| Earnings Date | Jul 15, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $269.95, which is an increase of 6.68% from the latest price.
News
Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter
As previously reported, Freedom Broker analyst Ilya Zubkov upgraded Johnson & Johnson to Buy from Hold with a price target of $280, up from $230, after “a strong quarterly performance”…
Johnson & Johnson upgraded to Buy from Hold at Freedom Broker
Freedom Broker upgraded Johnson & Johnson to Buy from Hold with a $280 price target
Johnson & Johnson price target raised to $305 from $265 at Scotiabank
Scotiabank raised the firm’s price target on Johnson & Johnson to $305 from $265 and keeps an Outperform rating on the shares. The firm is raising its price target following…
Johnson & Johnson price target raised to $265 from $258 at Raymond James
Raymond James raised the firm’s price target on Johnson & Johnson to $265 from $258 and keeps an Outperform rating on the shares. Continued momentum demonstrated in Q2 gives the…
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare profe...
DePuy Synthes Acquires Expanding Innovations™
RAYNHAM, Mass.--(BUSINESS WIRE)--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable...
Johnson & Johnson price target raised to $282 from $275 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Johnson & Johnson to $282 from $275 and keeps a Buy rating on the shares after its Q2 results. The overarching theme…
Johnson & Johnson price target raised to $270 from $260 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Johnson & Johnson to $270 from $260 and keeps a Neutral rating on the shares.
Johnson & Johnson price target raised to $294 from $284 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $294 from $284 and keeps an Overweight rating on the shares after the company posted…
Johnson & Johnson price target raised to $272 from $263 at Wells Fargo
Wells Fargo raised the firm’s price target on Johnson & Johnson to $272 from $263 and keeps an Overweight rating on the shares. The firm notes that cardio was unexpectedly…
Johnson & Johnson price target raised to $260 from $250 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Johnson & Johnson to $260 from $250 and keeps a Hold rating on the shares. The company delivered “solid” Q2…
J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue
The launch of artificial intelligence-powered imaging and mapping capabilities for electrophysiology, early momentum for a drug releasing system for bladder cancer treatment, and progress toward a tab...
Johnson & Johnson: Expiration of ACA subsidies won’t impact procedure demand
Does not expect expiration of Affordable Care Act subsidies to materially impact demand for MedTech and procedures.
Johnson & Johnson Stock (JNJ) Falls despite Q2 Beat, Higher Sales Forecast for 2026
Shares in Johnson & Johnson ($JNJ) dropped about 3% early Wednesday. This came even though the U.S. pharma giant surpassed Wall Street’s sales and profit estimates for its second quarter.
Johnson & Johnson says three of four business units accelerated through Q2
Says “confidently addressing” the fourth business unit. Says procedure volumes stable, not seeing evidence of a broad based slowdown in demand.
Johnson & Johnson expects operational sales growth to improve in 2H26
Expects stronger growth in MedTech unit in 2H26 vs.1H26.
Johnson & Johnson says capital allocation priorities remain unchanged
Says expects to return cash to shareholders mainly through the dividend.
Johnson & Johnson says confident in long term projections of Medtech business
08:54 EDT Johnson & Johnson says confident in long term projections of Medtech business
Johnson & Johnson says has strongest portfolio, pipeline in company’s history
Says pleased with progress of new launches. Expects momentum to accelerate into 2027 and beyond. Says on track to be number one oncology company by 2030. Says confidence rooted in…
Johnson & Johnson Earnings Call Transcript: Q2 2026
Q2 sales grew 5.6% to $25.3B, with double-digit growth excluding STELARA. Full-year 2026 guidance was raised, driven by strong performance in Innovative Medicine and new launches. MedTech growth is expected to accelerate in the second half, with robust cash flow and continued investment in innovation.
Johnson & Johnson Slides: Q2 2026
Johnson & Johnson has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 15, 2026.
Johnson & Johnson Earnings release: Q2 2026
Johnson & Johnson released its Q2 2026 earnings on July 15, 2026, summarizing the period's financial results.
ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market
Stocks look set to build on their recent gains as investors try to make sense of another batch of quarterly earnings reports.
Johnson & Johnson Hikes Guidance, Stock Falls
The drugmaker posts earnings that narrowly beat expectations and raises its full-year outlook.
Johnson & Johnson Bumps Up Guidance as Sales Rise
The drug and medical-device maker raised its forecast for the year after recording higher sales in the second quarter.